Olympus announced that the U.S. FDA had issued an import alert for its products. The facilities concerned are Olympus Medical Systems, Shirakawa Olympus and Aomori Olympus, and imports into the U.S. will be restricted until further notice.
Olympus announced that the U.S. FDA had issued an import alert for certain products manufactured at its facilities. The three facilities concerned are Olympus Medical Systems, Shirakawa Olympus and Aomori Olympus, and imports into the U.S. are expected to be restricted until further notice. As a result, shipments of the affected products to the U.S. market could be suspended for the time being.
After reviewing the scope of the measure’s impact, Olympus said it expected no additional impact on consolidated results for FY2027.3 and that it had made no changes to its earnings forecast for the fiscal year. The market may continue to monitor developments regarding future notifications while taking note of this point.